Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Google Secures Pentagon AI Deal for Classified Projects 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
Sun Pharma to Acquire Organon in $11.75 Billion Deal to Boost Global Women’s Health Portfolio 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
SAN DIEGO, Feb. 19, 2016 -- TearLab Corporation (NASDAQ:TEAR) (TSX:TLB) (“TearLab” or the “Company”) will announce its fourth quarter and full year 2015 financial results after market close on Tuesday, March 8, 2016.
TearLab’s Chief Executive Officer, Seph Jensen and Chief Financial Officer, Wes Brazell, will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period.
Fourth Quarter and Full Year 2015 Results Conference Call Details:
Date: Tuesday, March 8, 2016
Time: 4:30 p.m. ET
Live Call: 877-303-1593
Replay: 855-859-2056 (Pass Code: 54603879)
The call will also be broadcast live and archived on the Company's website at www.tearlab.com under the "Webcasts" tab in the Investor's section.
About TearLab Corporation
TearLab Corporation (www.tearlab.com) develops and markets lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The TearLab Osmolarity® Test, for diagnosing Dry Eye Disease, is the first assay developed for the award-winning TearLab Osmolarity System. TearLab Corporation's common shares trade on the NASDAQ Capital Market under the symbol 'TEAR' and on the Toronto Stock Exchange under the symbol 'TLB'.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among others, statements concerning our future financial performance, the future success and performance of our principal product and the future status of reimbursement for our technology. These forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are based on management's current, preliminary expectations and are subject to various risks and uncertainties. Many factors, risks and uncertainties may cause our actual results to differ materially from forward-looking statements, including the factors, risks, and uncertainties detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 13, 2015, and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2015 filed with the SEC on November 6, 2015. We do not undertake to update any forward-looking statements.
CONTACTS: Investors: Stephen Kilmer (647) 872-4849 [email protected]
